Followers | 3352 |
Posts | 85154 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Friday, October 13, 2023 12:07:44 PM
October 11 2023 - 04:00PM
GlobeNewswire Inc.
Alert
Share On Facebook
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.
“Our OMEGA platform enables us to rationally and rapidly design epigenomic controllers to bidirectionally tune the expression of one or multiple genes pre-transcriptionally,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. “These preclinical data demonstrate the potential of programmable mRNA development candidates to controllably upregulate the expression of a single gene to drive liver regeneration in models of fibrosis, as well as the ability to simultaneously downregulate the expression of multiple genes linked to inflammatory liver diseases with a single epigenomic controller. Together, these findings underscore the versatile capabilities of our OMEGA platform and the potential of precision epigenomic control to address a broad range of diseases.”
Details for the poster presentations are as follows:
Title: Targeting CXCL9/CXCL10/CXCL11 using novel epigenomic controllers for the treatment of inflammatory liver disease
Poster number: 2621-A
Date and Time: November 11, 2023, from 1:00 p.m. to 2:00 p.m. ET
This poster has been selected by AASLD as a “Poster of Distinction”, having been classified as being in the top 5% of scored poster abstracts and will receive special recognition in the Poster Hall.
Title: Induction of Hepatocyte Nuclear Factor 4 alpha (HNF4a) using novel epigenomic controllers
Poster number: 3444-A
Date and Time: November 12, 2023, from 1:00 p.m. to 2:00 p.m. ET
The posters will be made available on the Omega website at https://omegatherapeutics.com/our-science/#publications-research at the same time as the presentations.
About the OMEGA Platform
The OMEGA platform leverages the Company’s deep understanding of gene regulation, genomic architecture and epigenetic mechanisms to design programmable epigenomic mRNA medicines that precisely target and modulate gene expression at the pre-transcriptional level. Combining a biology-first approach and world-class data science capabilities with rational drug design and customized delivery, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range. Omega’s investigational programmable mRNA medicines, Epigenomic Controllers, target specific genomic loci within insulated genomic domains with high specificity to durably tune single or multiple genes to treat and cure diseases through unprecedented precision epigenomic control.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on X (formerly Twitter) and LinkedIn.
Recent OMGA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:57:45 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/30/2024 09:10:10 PM
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:59 AM
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer • GlobeNewswire Inc. • 05/29/2024 11:00:17 AM
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 11:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:04:21 AM
- Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/06/2024 11:00:02 AM
- Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/23/2024 11:00:02 AM
- Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control • GlobeNewswire Inc. • 04/09/2024 11:00:31 AM
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update • GlobeNewswire Inc. • 03/28/2024 01:15:05 PM
- Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:14:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:00:18 PM
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 09:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 12/04/2023 09:00:22 PM
- Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders • PR Newswire (US) • 11/28/2023 12:01:00 AM
- Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics • PR Newswire (US) • 11/21/2023 11:00:00 AM
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 09:00:00 PM
- Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis • GlobeNewswire Inc. • 11/13/2023 12:00:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:03:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:03:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM